Octreotide extended release - Xbrane

Drug Profile

Octreotide extended release - Xbrane

Alternative Names: Octreosphere

Latest Information Update: 30 Oct 2015

Price : $50

At a glance

  • Originator Primm srl
  • Developer Xbrane
  • Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
  • Mechanism of Action Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acromegaly; Diarrhoea; Intestinal obstruction; Neuroendocrine tumours

Most Recent Events

  • 30 Oct 2015 Preclinical trials in Neuroendocrine tumours in Sweden (IV-injection)
  • 30 Oct 2015 Preclinical trials in Intestinal obstruction in Sweden (IV-injection)
  • 30 Oct 2015 Preclinical trials in Diarrhoea in Sweden (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top